Dose Finding Pilot Study of Cabozantinib (XL184) Administered Orally as Monotherapy for the Treatment of Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With Bone Disease
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Biomarker
- 10 Jun 2017 Biomarkers information updated
- 25 Feb 2017 Status changed from active, no longer recruiting to completed.
- 28 Mar 2016 Pooled analysis of 2 studies of 12 patients (NCT01866293 and NCT01582295) published in the Blood.